Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Left Atrial Appendage Closure: Effective to Reduce Risk of Stroke?

Original Title: Effectiveness of Left Atrial Appendage Exclusion Procedures to Reduce the Risk of Stroke: A Systematic Review of the Evidence.

Reference: North Noelck et al. Circ Cardiovasc Qual Outcomes. July 2016. Published ahead of print.

 
Left Atrial Appendage ClosureAtrial fibrillation is an important cause of stroke. Oral anticoagulation reduces the risk of stroke but, on the other hand, increases the risk of bleeding. Left atrial appendage closure procedures have been designed to isolate the left atrial appendage (LAA) from blood circulation and is an alternative to oral anticoagulation.

This study is a systematic review to assess the risks and benefits of percutaneous or surgical LAA closure.

In all, 20 studies met the pre-specified inclusion criteria, from where researchers recovered patient characteristics, and stroke, mortality and adverse events rates.  The quality and state of evidence were also assessed according to publication criteria.

Researchers found studies with low quality evidence concluding LAA closure and anticoagulation had similar risk of stroke and mortality rates, noting, however, this evidence was limited to Watchman implantation in patients eligible for oral anticoagulation at short term.

Observational studies provide stronger evidence on the possibility of periprocedural adverse events after percutaneous LAA closure with practically all available devices.

There is little evidence on surgical LAA closure in the context of heart surgery for another indication (either cardiac or vascular), but it doesn’t seem to contribute to surgery-related adverse events that. There is insufficient data to argue that surgery will reduce stroke risk.

 

Conclusion

There is limited evidence to support the Watchman might be superior to long term oral anticoagulation in selected patients. There is not enough data on the effectiveness of different devices in patients who are ineligible for oral anticoagulation. Percutaneous LAA closure is associated with a relatively high risk of periprocedural complications.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...